Summary The first proposed hypothesis about the mechanism of chloroquine (CQ) action on malaria parasites is DNA intercalation hypothesis which indicates that the site of CQ action is within nucleus. Later on the interest of research was shifted from nucleus to lysosome due to the report of CQ accumulation within lysosome. The current opinions about CQ action and resistance are mainly based on the results of more than 30 years' studies on lysosome, which can be used to explain some facts but still remains incomplete and controversial. Based on recently published papers and our related data it is possible that the key CQ target protein may exist in nucleus. Development of CQ resistance is probably mainly due to the alteration in the CQ target protein or certain mechanism which prevents CQ from reaching its target protein in nucleus. In conclusion, the key site of CQ action may be in nucleus though it has not been well explored while CQ action in lysosome which has been well studied may be secondarily important in CQ action and resistance.
Introduction
Chloroquine (CQ) resistance is still a big problem in chemotherapy of malaria for it is responsible for increased morbidity and mortality of the disease [1] . Understanding of the mechanism by which CQ exerts its action and the mechanism by which malaria parasites become CQ resistant will contribute to overcoming of the resistance and designing of new antimalarials.
The first hypothesis about the mechanism of CQ action on malaria parasites is DNA intercalation hypothesis [2, 3] , which clearly indicates that CQ action site is in nucleus but further detailed researches on this hypothesis were interrupted by the report of CQ accumulation and action in lysosome [4, 5] , which had drawn people's attention from nucleus to lysosome (food vacuole) because it is believed that drug accumulation site is usually the site of action. Since then the majority of researches on CQ action and resistance have been carried out around lysosome. But after more than 30 years' studies the mechanisms of CQ action and resistance remain controversial.
In this article a novel hypothesis about the mechanisms of CQ action and resistance is presented, which is based on critical review of current mainstream opinions about CQ action and our related evidence that challenges the mainstream idea.
Arguments against current CQ-lysosome action hypothesis
The current mainstream opinions about CQ action could be called CQ-lysosome action hypothesis, which is based on the findings of more than 30 years' studies on the lysosome. CQ is a weak-base drug and accumulated several thousand-fold in parasites' acidic lysosome. The CQ target in lysosome is ferriprotoporphyrin IX (FPIX) which is a non-protein molecule, and produced in Plasmodium lysosome during digestion of haemoglobin. The FPIX is toxic and can lyse biomembrane [6, 7] . The detoxification of FPIX in malaria parasite is achieved by polymerization of FPIX into a non-toxic crystal of hemozoin. CQ can bind to FPIX to form a CQ-FPIX complex which is more toxic to biomembrane. It is thought that CQ kills parasites by inhibiting polymerization of FPIX moieties into hemozoin [8] .
The main argument against the CQ-lysosome action hypothesis perhaps is the CQ target. There are several reasons to argue that the key target of CQ antimalarial action may not be FPIX. Firstly, some known drug's action targets exclusively belong to proteins and their resistances are caused by alteration in these targets or in the metabolic pathway. Secondly, it is accepted that the earliest change in parasites after CQ action is swollen lysosome [5, 9] . Since free FPIX and CQ-FPIX complex are toxic to biomembrane and large amount of CQ and free FP are accumulated in lysosome (it is said that only 20-30% of free FPIX is incorporated into non-toxic hemozoin), the total effects of CQ and FPIX on lysosome membrane will be so disastrous that they will completely destroy the lysosome, not just make it swollen. Thirdly, CQ can cause similar changes in lung cancer cell that contains no FPIX [10] .
The other argument is that CQ accumulated in lysosome does not definitely mean that its key site of action is in lysosome. NH 4 Cl is a weak base substance and can be accumulated in lysosome of malaria parasites. Washing of parasite-infected red blood cells after CQ exposure in the presence of NH 4 Cl accelerated the drug efflux from lysosome but also intensified the CQ antimalarial action [11] . This study indicates that the key site of CQ action is outside the lysosome. It is reported recently that CQ had different actions on A549 lung cancer cell. At lower concentration it inhibited the cell growth by increasing the volume of lysosomes, and at higher concentration it induced apoptosis and necrosis without further damaging lysosome [10] , which suggests that the key site of CQ action is not in lysosome, most likely in nucleus.
According to the CQ-lysosome action hypothesis CQ resistance in malaria parasites is caused by reduced CQ concentration in lysosome. Several hypotheses have been proposed for this, including drug efflux, modified lysosome pH, the role of Na + /H + exchanger, and transporters etc. [8, 12] . But none of them can link the resistance to CQ target molecule, FPIX.
So far 3 genes including pfmdr1, cg2, pfcrt have been reported to be associated with CQ resistance because their polymorphisms are correlated more or less with the CQ phenotype [13] [14] [15] . Since all these genes' products are found in the membrane of lysosome it is reasonable to believe that the site of CQ action and resistance development is within lysosome. But there is another explanation: why in lysosome membrane are there so many ''CQresistance-associated molecules''? One simple answer is that none of them is specifically involved in development of CQ resistance, most likely they may be just involved in protection or maintenance of lysosome functions through reducing CQ concentration in lysosome, and under long-term CQ selection, their mutant molecules could be produced in CQ-resistant isolates. Of cause, protection of lysosome might contribute some to development of resistance to CQ.
Evidence for CQ-nucleus action
Early researches demonstrated that at high concentrations CQ can interact with or bind to both DNA and RNA, leading to the inhibition of DNA replication and RNA synthesis [2, 3] . The mechanism of CQ antimalarial action was originally thought in the similar way, which is known as DNA intercalation hypothesis. After report of CQ accumulation and action in lysosome of malaria parasites, the majority of interest had shifted away from nucleus to lysosome. But more than 30 years passed the mechanisms of CQ action and resistance development are still unclear, which makes some scientists to rethink about CQ action in nucleus [16, 17] .
In 1997, a published paper showed that after CQ treatment, oligonucleosomal DNA fragmentation was observed with a sensitive strain of P. falciparum, but not with a resistant one, suggesting that apoptosis may be involved in the action of CQ on the parasite [18] . Recent report that CQ can stimulate p53-apoptotic pathway in rat hepatocytes supports the apoptosis hypothesis for CQ antimalarial action [19] . Another evidence of CQ action in nucleus comes from a report that CQ and other quinoline-like compounds interfered with the DNA synthesis step of the repair process, suggesting that altered DNA repair may contribute to the development of drug resistance in malaria parasites [20] .
To prove CQ action in nucleus, we also did some experiments around late 1998 and early 1999. The K1 CQ-resistant and HB3 CQ-sensitive isolates of Plasmodium falciparum were treated with CQ at its respective IC 10 , IC 50 , and IC 99 concentrations. Genomic DNA was isolated, using standard procedure (proteinase K digestion overnight followed by twice phenol/chloroform extractions), at intervals of 2 h, 6 h, 12 h, and 24 h after CQ treatment, and subject to polymerase chain reaction (PCR) using an arbitrary GC-rich primer (5 0 -GAATTCGCGGCCGCAGGAAT-3 0 ). The PCR-banding patterns of both CQ treated and control groups displayed time dependent changes and there was marked difference between the CQ treated and control groups [unpublished data]. The results indicate that CQ does exert its action in nucleus.
We once proposed a hypothesis that CQ-resistant malaria parasites might produce a certain ''specific anti-drug substance'' which can specifically band to CQ and thus prevents CQ from reaching its action target [21] . Recently published papers showed that some parts of CQ-resistant parasite lysates and purified plasma membrane of CQ-resistant parasites bind more CQ than those of CQ-sensitive parasites [22, 23] , which indicates that CQ-resistant parasites may produce specific CQ binding protein, but whether the CQ-binding protein comes from nucleus is unknown.
In 1998, we cloned a DNA fragment (AAL55474) which is associated with CQ resistance, later on 3 complete sequences of the same gene were submitted to GenBank (AAK48418, AAK49448, AAK49449). The gene encodes a nuclear protein which is named as CQ resistance marker protein due to good correlation between its polymorphisms and CQ resistance. In the GenBank released sequences there is a note about the gene which states ''approximately 430 kDa; immuno-electron microscopy studies revealed that this product was found exclusively within the nucleus in the chloroquine-sensitive HB3 strain, but was scattered inside the cytoplasm or around the nucleus in the chloroquine-resistant K1 strain, indicating a possible role of the protein in chloroquine action and resistance''.
Till now we do not know exactly the location of the key CQ target protein, but based on the published papers and our related data as mentioned above, it is possible that the key CQ target protein is located in nucleus.
CQ-nucleus action hypothesis
As indicated above, the key site of CQ antimalarial action may be located in nucleus. If this is true the accumulation of CQ in lysosome will benefit the parasite's survival because this accumulation can reduce the drug pressure on the key site of action, nucleus. Besides, processed CQ in lysosome such as CQ-FPIX complex might be difficult to enter nucleus, which also contributes to reduction of drug pressure on the nucleus. Therefore lysosome accumulation of CQ can be considered as a parasite's antidrug buffering response to CQ toxicity. This antidrug buffering response is nonspecific, and exists in both CQ-sensitive and CQ-resistant parasites. In CQ-sensitive parasites CQ concentration in nucleus is probably much lower than that in lysosome, but it is enough to kill the parasites because the key CQ target protein is in nucleus. Development of CQ-resistance is probably mainly due to the alteration in the CQ target protein or certain mechanism which prevents CQ from reaching its action target in nucleus.
It is obvious that large amount of CQ accumulated in lysosome will damage or change some lysosome's structure and functions, which might affect the parasite's growth, but may not cause the death of parasites. Therefore CQ action in lysosome may contribute some to CQ antimalarial action.
Conclusion
The sites of CQ action and resistance development may include both nucleus and lysosome. Since the key CQ target protein may be located in nucleus of malaria parasites the nucleus in which CQ action has not been well explored may be the key site of CQ action and resistance development while lysosome in which CQ action has been well studied might be the secondarily important site. At present, more emphasis should be placed on studies of CQ action in nucleus of malaria parasites.
